Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

707 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
Bhatia V, Kamat NV, Pariva TE, Wu LT, Tsao A, Sasaki K, Sun H, Javier G, Nutt S, Coleman I, Hitchcock L, Zhang A, Rudoy D, Gulati R, Patel RA, Roudier MP, True LD, Srivastava S, Morrissey CM, Haffner MC, Nelson PS, Priceman SJ, Ishihara J, Lee JK. Bhatia V, et al. Among authors: gulati r. Nat Commun. 2023 Apr 11;14(1):2041. doi: 10.1038/s41467-023-37874-2. Nat Commun. 2023. PMID: 37041154 Free PMC article.
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.
Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni RD, Higano CS. Yu EY, et al. Among authors: gulati r. J Clin Oncol. 2010 Jun 1;28(16):2668-73. doi: 10.1200/JCO.2009.25.1330. Epub 2010 Apr 26. J Clin Oncol. 2010. PMID: 20421544 Free PMC article. Clinical Trial.
Single cell transcriptomic analysis of prostate cancer cells.
Welty CJ, Coleman I, Coleman R, Lakely B, Xia J, Chen S, Gulati R, Larson SR, Lange PH, Montgomery B, Nelson PS, Vessella RL, Morrissey C. Welty CJ, et al. Among authors: gulati r. BMC Mol Biol. 2013 Feb 16;14:6. doi: 10.1186/1471-2199-14-6. BMC Mol Biol. 2013. PMID: 23414343 Free PMC article.
Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B. Mostaghel EA, et al. Among authors: gulati r. J Clin Oncol. 2014 Jan 20;32(3):229-37. doi: 10.1200/JCO.2012.48.6431. Epub 2013 Dec 9. J Clin Oncol. 2014. PMID: 24323034 Free PMC article. Clinical Trial.
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.
Gordon RR, Wu M, Huang CY, Harris WP, Sim HG, Lucas JM, Coleman I, Higano CS, Gulati R, True LD, Vessella R, Lange PH, Garzotto M, Beer TM, Nelson PS. Gordon RR, et al. Among authors: gulati r. PLoS One. 2014 Sep 8;9(9):e104271. doi: 10.1371/journal.pone.0104271. eCollection 2014. PLoS One. 2014. PMID: 25198178 Free PMC article. Clinical Trial.
Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways.
Chéry L, Lam HM, Coleman I, Lakely B, Coleman R, Larson S, Aguirre-Ghiso JA, Xia J, Gulati R, Nelson PS, Montgomery B, Lange P, Snyder LA, Vessella RL, Morrissey C. Chéry L, et al. Among authors: gulati r. Oncotarget. 2014 Oct 30;5(20):9939-51. doi: 10.18632/oncotarget.2480. Oncotarget. 2014. PMID: 25301725 Free PMC article.
707 results